Tadeusz Robak

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 89

Top Topics

Multiple Myeloma

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

Leukemia & lymphoma

Journal of clinical medicine

International journal of molecular sciences

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology (2024)
Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update. Annals of hematology 103 (9) (2024)
Michael R Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Claire Dearden, Sascha Dietrich, Monica Else, Narendranath Epperla, Andrei Fagarasanu, Brunangelo Falini, Francesco Forconi, Alessandro Gozzetti, Paul Joseph Hampel, David J Hermel, Sunil Iyengar, James B Johnston, Gunnar Juliusson, Robert J Kreitman, Francesco Lauria, Gerard Lozanski, Christopher C Oakes, Sameer A Parikh, Jae H Park, Graeme Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Enrico Tiacci, Xavier Troussard, Bernhard J Woermann, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani
Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia 38 (7) (2024)
Tomasz Stein, Tadeusz Robak, Wojciech Biernat, Ewa Robak
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. Journal of clinical medicine 13 (3) (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology 20 (4) (2024)
Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update. Annals of hematology 103 (9) (2024)
Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. International journal of molecular sciences 25 (3) (2024)
Michael L Wang, Tadeusz Robak, Kami J Maddocks, Tycel Jovelle Phillips, Stephen Douglas Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood advances (2024)
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jarosław Czyż, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Lukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H Cooperrider, Andrzej J Jakubowiak, Benjamin A Derman
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood 144 (9) (2024)
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jarosław Czyż, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Lukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H Cooperrider, Andrzej J Jakubowiak, Benjamin A Derman
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood 144 (9) (2024)
Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Pawel Robak
Successful treatment with cladribine in a patient with Rosai-Dorfman disease complicated by severe, prolonged marrow aplasia. Leukemia & lymphoma (2024)
Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. International journal of molecular sciences 25 (3) (2024)
Michael R Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Claire Dearden, Sascha Dietrich, Monica Else, Narendranath Epperla, Andrei Fagarasanu, Brunangelo Falini, Francesco Forconi, Alessandro Gozzetti, Paul Joseph Hampel, David J Hermel, Sunil Iyengar, James B Johnston, Gunnar Juliusson, Robert J Kreitman, Francesco Lauria, Gerard Lozanski, Christopher C Oakes, Sameer A Parikh, Jae H Park, Graeme Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Enrico Tiacci, Xavier Troussard, Bernhard J Woermann, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani
Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia 38 (7) (2024)
Tadeusz Robak, Marcin Braun, Agnieszka Janus, Anna Guminska, Ewa Robak
Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview. Cancers 16 (17) (2024)
Tomasz Stein, Tadeusz Robak, Wojciech Biernat, Ewa Robak
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. Journal of clinical medicine 13 (3) (2024)
Michael R Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Claire Dearden, Sascha Dietrich, Monica Else, Narendranath Epperla, Andrei Fagarasanu, Brunangelo Falini, Francesco Forconi, Alessandro Gozzetti, Paul Joseph Hampel, David J Hermel, Sunil Iyengar, James B Johnston, Gunnar Juliusson, Robert J Kreitman, Francesco Lauria, Gerard Lozanski, Christopher C Oakes, Sameer A Parikh, Jae H Park, Graeme Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Enrico Tiacci, Xavier Troussard, Bernhard J Woermann, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani
Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia 38 (7) (2024)
Tadeusz Kubicki, Dominik Dytfeld, David R Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Agata Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Anna Gil, Bartosz Puła, Lukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer Helen Cooperrider, Andrzej J Jakubowiak, Benjamin A Derman
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma. Blood (2024)
Michael L Wang, Tadeusz Robak, Kami J Maddocks, Tycel Jovelle Phillips, Stephen D Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood advances 8 (17) (2024)
Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. International journal of molecular sciences 25 (3) (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology 20 (4) (2024)
Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. International journal of molecular sciences 25 (3) (2024)
Michael L Wang, Tadeusz Robak, Kami J Maddocks, Tycel Jovelle Phillips, Stephen D Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood advances 8 (17) (2024)
Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update. Annals of hematology (2024)
Michael R Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Claire Dearden, Sascha Dietrich, Monica Else, Narendranath Epperla, Andrei Fagarasanu, Brunangelo Falini, Francesco Forconi, Alessandro Gozzetti, Paul Joseph Hampel, David J Hermel, Sunil Iyengar, James B Johnston, Gunnar Juliusson, Robert J Kreitman, Francesco Lauria, Gerard Lozanski, Christopher C Oakes, Sameer A Parikh, Jae H Park, Graeme Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Enrico Tiacci, Xavier Troussard, Bernhard J Woermann, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani
Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia (2024)
Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Pawel Robak
Successful treatment with cladribine in a patient with Rosai-Dorfman disease complicated by severe, prolonged marrow aplasia. Leukemia & lymphoma 65 (8) (2024)
Michael R Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Claire Dearden, Sascha Dietrich, Monica Else, Narendranath Epperla, Andrei Fagarasanu, Brunangelo Falini, Francesco Forconi, Alessandro Gozzetti, Paul Joseph Hampel, David J Hermel, Sunil Iyengar, James B Johnston, Gunnar Juliusson, Robert J Kreitman, Francesco Lauria, Gerard Lozanski, Christopher C Oakes, Sameer A Parikh, Jae H Park, Graeme Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Enrico Tiacci, Xavier Troussard, Bernhard J Woermann, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani
Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia 38 (7) (2024)
Jennifer A Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Arpad Illes, Arnon P Kater, Paolo Ghia, John C Byrd, John Francis Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib. Blood (2024)
Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update. Annals of hematology 103 (9) (2024)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Pierre Fenaux, Marco Gobbi, Patricia Kropf, Jean-Pierre J Issa, Gail J Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novak, Wieslaw Wiktor Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Todorova Gercheva-Kyuchukova, Judit Demeter, Elizabeth A Griffiths, Karen W L Yee, Konstanze Döhner, Yong Hao, Harold Neal Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood advances (2023)
Aleksandra Gołos, Joanna Góra-Tybor, Tadeusz Robak
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert opinion on investigational drugs 32 (1) (2023)
Tara Cochrane, Alicia Enrico, Guillermo José Ruiz Argüelles, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene A Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy. Leukemia & lymphoma (2023)
Pawel Robak, Magda Witkowska, Anna Wolska-Washer, Tadeusz Robak
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert opinion on drug discovery (2023)
Tadeusz Robak
Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia? Leukemia & lymphoma (2023)
Tadeusz Robak, Paweł Robak
Refractory and relapsed hairy-cell leukemia (HCL): Casting light on promising experimental drugs in clinical trials. Expert opinion on investigational drugs (2023)
Tadeusz Robak, Anna Krawczyńska, Barbara Cebula-Obrzut, Marta Urbaniak, Elżbieta Iskierka-Jażdżewska, Pawel Robak
Atypical Chronic Lymphocytic Leukemia-The Current Status. Cancers 15 (18) (2023)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Anna Puła, Tadeusz Robak, Izabela Dróżdż, Konrad Stawiski, Aleksander Rycerz, Małgorzata Misiewicz, Pawel Robak
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study. Leukemia & lymphoma (2023)
Mikkael A Sekeres, Pau Montesinos, Jan Novak, Jian-Xiang Wang, Deepa Jeyakumar, Benjamin K Tomlinson, Jiri Mayer, Erin Jou, Tadeusz Robak, David C Taussig, Hervé Dombret, Akil A Merchant, Naveed Shaik, Thomas O'Brien, Whijae Roh, Xueli Liu, Wendy Ma, Christine G DiRienzo, Geoffrey Chan, Jorge E Cortes
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia (2023)
Ewa Robak, Marcin Braun, Tadeusz Robak
Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment. Cancers 15 (22) (2023)
Aleksandra Gołos, Joanna Góra-Tybor, Tadeusz Robak
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert opinion on investigational drugs 32 (1) (2023)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Aleksandra Gołos, Joanna Góra-Tybor, Tadeusz Robak
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert opinion on investigational drugs (2023)
Tadeusz Robak, Pawel Robak
Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials. Expert opinion on investigational drugs (2023)
Magdalena Witkowska, Agata Majchrzak, Pawel Robak, Anna Wolska-Washer, Tadeusz Robak
Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia. Expert opinion on drug metabolism & toxicology (2023)
Tadeusz Robak, Jaroslaw D Kasprzak, Dorota Jesionek-Kupnicka, Michał Soin, Pawel Robak
Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis. Leukemia & lymphoma 64 (4) (2023)
Aleksandra Gołos, Joanna Góra-Tybor, Tadeusz Robak
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert opinion on investigational drugs 32 (1) (2023)
Aleksandra Gołos, Joanna Góra-Tybor, Tadeusz Robak
Experimental drugs in clinical trials for acute myeloid leukemia: Innovations, trends and opportunities. Expert opinion on investigational drugs (2023)
Tahla Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P Kater
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
John Francis Seymour, Thomas J Kipps, Barbara F Eichhorst, James D'Rozario, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de laSerna, Ulrich Jäger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P Kater
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140 (8) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, James S Blachly, Puneet Mathur, Omkar Lele, Claire Dearden, Sunil Iyengar, Matthew Cross, Clive S Zent, Kerry A Rogers, Narendranath Epperla, Gerard Lozanski, Christopher C Oakes, Eric Kraut, Amy S Ruppert, Qiuhong Zhao, Seema A Bhat, Francesco Forconi, Versha Banerji, Sasanka Handunnetti, Constantine S Tam, John F Seymour, Monica Else, Robert J Kreitman, Alan Saven, Timothy Call, Sameer A Parikh, Farhad Ravandi, James B Johnston, Enrico Tiacci, Xavier Troussard, Martin S Tallman, Sascha Dietrich, Tamar Tadmor, Alessandro Gozzetti, Pier Luigi Zinzani, Tadeusz Robak, Graeme Quest, Judit Demeter, Kanti Rai, Soledad A Fernandez, Michael Grever
Development of a distributed international patient data registry for hairy cell leukemia. Leukemia & lymphoma (2022)
Ewa Robak, Tadeusz Robak
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Journal of clinical medicine 11 (10) (2022)
Damian Mikulski, Pawel Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra-Tybor, Tadeusz Robak
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of clinical medicine 11 (19) (2022)
Jan A Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A Stevens, Sandra Dai, Leo W K Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J Kipps, Alessandra Tedeschi
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leukemia & lymphoma 63 (6) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Elżbieta Iskierka-Jazdzewska, Agnieszka Obracaj, Marta Urbaniak, Tadeusz Robak
New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. Current treatment options in oncology 23 (6) (2022)
Pawel Robak, Tadeusz Robak
Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert opinion on biological therapy (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger, Peter Hillmen, Steve E Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J Kipps, Paolo Ghia
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood advances 6 (11) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Tadeusz Robak, Magda Witkowska, Piotr Smolewski
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers 14 (3) (2022)
Tadeusz Robak, Jaroslaw D Kasprzak, Dorota Jesionek-Kupnicka, Cezary Chudobiński, Pawel Robak
Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of clinical medicine 11 (23) (2022)
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novák, Wieslaw Wiktor Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A Griffiths, Karen W L Yee, Jean-Pierre J Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 140 (3) (2022)
Anna Wolska-Washer, Tadeusz Robak
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert review of hematology 15 (3) (2022)
Tadeusz Robak, Jaroslaw D Kasprzak, Dorota Jesionek-Kupnicka, Cezary Chudobiński, Pawel Robak
Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of clinical medicine 11 (23) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Tadeusz Robak, Jaroslaw D Kasprzak, Dorota Jesionek-Kupnicka, Cezary Chudobiński, Pawel Robak
Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of clinical medicine 11 (23) (2022)
Iwona Hus, Bartosz Puła, Tadeusz Robak
PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. Cancers 14 (6) (2022)
Alessandro Broccoli, Lisa Argnani, Matthew Cross, Agnieszka Janus, Elsa Maître, Xavier Troussard, Tadeusz Robak, Claire Dearden, Monica Else, Daniel Catovsky, Pier Luigi Luigi Zinzani
A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood advances 6 (14) (2022)
Ewa Robak, Dorota Jesionek-Kupnicka, Piotr Stelmach, Piotr Kupnicki, Magdalena Szataniak, Tadeusz Robak
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab. Annals of hematology 101 (6) (2022)
Tara Cochrane, Alicia Enrico, Guillermo José Ruiz Argüelles, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene A Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Kavita R Sail, John C Pesko, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leukemia & lymphoma (2021)
Paweł Robak, Janusz Zbigniew Szemraj, Damian Mikulski, Izabela Dróżdż, Karolina Juszczak, Dariusz Jarych, Małgorzata Misiewicz, Kacper Kościelny, Wojciech Fendler, Tadeusz Robak
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of clinical medicine 10 (21) (2021)
Nina D Wagner-Johnston, Jeff Sharman, Richard R Furman, Gilles Salles, Jennifer R Brown, Tadeusz Robak, Lin Gu, Guan Xing, Rebecca J Chan, Nishanthan Rajakumaraswamy, Ajay K Gopal
Idelalisib immune-related toxicity is associated with improved treatment response. Leukemia & lymphoma 62 (12) (2021)
Anna Puła, Paweł Robak, Damian Mikulski, Tadeusz Robak
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. International journal of molecular sciences 22 (21) (2021)
Tadeusz Robak, Agnieszka Janus, Krzysztof Jamroziak, Enrico Tiacci, Robert J Kreitman
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of clinical medicine 10 (13) (2021)
Pawel Robak, Dariusz Jarych, Damian Mikulski, Izabela Dróżdż, Edyta Węgłowska, Aleksandra Kotkowska, Małgorzata Misiewicz, Piotr Smolewski, Konrad Stawiski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers 13 (5) (2021)
Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John G Gribben, Lekh N Dahal, Mathew J Carter, Olivier Elemento, Dan A Landau, Donna S Neuberg, Mark S Cragg, Axel Benner, Michael Hallek, Catherine J Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature communications 12 (1) (2021)
Damian Mikulski, Paweł Robak, Ewelina Perdas, Edyta Węgłowska, Aleksandra Łosiewicz, Izabela Dróżdż, Dariusz Jarych, Małgorzata Misiewicz, Janusz Zbigniew Szemraj, Wojciech Fendler, Tadeusz Robak
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of clinical medicine 11 (1) (2021)
Ewa Robak, Dorota Jesionek-Kupnicka, Tadeusz Robak
Skin changes in hairy cell leukemia. Annals of hematology 100 (3) (2020)
Pawel Robak, Dorota Jesionek-Kupnicka, Piotr Kupnicki, Aaron Polliack, Tadeusz Robak
Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment. Annals of hematology 100 (6) (2020)
Paweł Robak, Izabela Dróżdż, Dariusz Jarych, Damian Mikulski, Edyta Węgłowska, Monika Siemieniuk-Ryś, Małgorzata Misiewicz, Konrad Stawiski, Wojciech Fendler, Janusz Szemraj, Piotr Smolewski, Tadeusz Robak
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers 12 (9) (2020)
Paweł Robak, Edyta Węgłowska, Izabela Dróżdż, Damian Mikulski, Dariusz Jarych, Magdalena Ferlińska, Ewa Wawrzyniak, Małgorzata Misiewicz, Piotr Smolewski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib. Mediators of inflammation 2020 (2020)
Susan M O'Brien, John C Byrd, Peter Hillmen, Steven Coutre, Jennifer R Brown, Paul M Barr, Jacqueline C Barrientos, Stephen Devereux, Tadeusz Robak, Nishitha M Reddy, Thomas J Kipps, Alessandra Tedeschi, Florence Cymbalista, Paolo Ghia, Stephen Chang, Joi Ninomoto, Danelle F James, Jan A Burger
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American journal of hematology 94 (5) (2019)
Anna Wolska-Washer, Tadeusz Robak
Glasdegib in the treatment of acute myeloid leukemia. Future oncology (London, England) 15 (28) (2019)
Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, Paul M Barr, Carolyn Owen, Osnat Bairey, Peter Hillmen, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen McCarthy, Steven E Coutre, Hang Quach, Gianluca Gaidano, Zvenyslava Maslyak, Don A Stevens, Carol Moreno, Devinder S Gill, Ian W Flinn, John G Gribben, Ahmad Mokatrin, Mei Cheng, Lori Styles, Danelle F James, Thomas J Kipps, Paolo Ghia
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. American journal of hematology 93 (11) (2018)
Jorge E Cortes, B Douglas Smith, Eunice S Wang, Akil Merchant, Vivian G Oehler, Martha Arellano, Daniel J DeAngelo, Daniel A Pollyea, Mikkael A Sekeres, Tadeusz Robak, Weidong Wendy Ma, Mirjana Zeremski, M Naveed Shaik, A Douglas Laird, Ashleigh O'Connell, Geoffrey Chan, Mark A Schroeder
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. American journal of hematology 93 (11) (2018)